University of Belgrade Launches Clinical Trial Comparing Tecnoss's GTO and Gen-Os for Periodontal Bone Defect Treatment
A Technological Turning Point in the Periodontal Tissue Regeneration Market
The dental bone grafting market, which aims to restore alveolar bone lost due to periodontal disease, is rapidly evolving to maximize patient recovery speed and convenience. The clinical trial, led by researchers at the University of Belgrade, is a head-to-head study that directly compares the efficacy of Gen-Os, a porcine-derived collagen bone graft from Tecnoss Dental, and GTO in treating periodontal bone defects. This study highlights the emergence of porcine bone-derived collagen-containing products as new alternatives, which are gradually absorbed and replaced by autologous bone, in a market previously dominated by Geistlich's Bio-Oss, a traditional non-absorbable bone-based material.
Verifying Synergistic Effects with Non-Incision Papilla Preservation Technique
This clinical trial goes beyond simply evaluating the performance of bone grafting materials and focuses on verifying the synergistic effects when combined with the non-incision papilla preservation technique, a minimally invasive surgical procedure. This technique minimizes gingival incisions, reducing postoperative pain and preventing gingival recession, significantly improving the patient's aesthetic outcomes. A key aspect of this comparative study is how effectively the injectable paste-form GTO and the existing granular Gen-Os are delivered and function as a support structure in the narrow gingival spaces.
Clinical Evaluation of Autologous Bone Replacement Rate and Mechanical Properties
The researchers will focus on analyzing key indicators that determine the success of alveolar bone regeneration, including clinical attachment gain and radiographic bone fill in the defect area. GTO is formulated by mixing 60% Gen-Os granules with 40% thermosensitive hydrogel, which solidifies at body temperature, making it highly user-friendly in clinical settings. This study aims to determine the biological differences in regeneration quality beyond simple external restoration by tracking how these material differences affect the microbial composition and inflammatory response within the periodontal pocket.
Standard Competition in the Premium Dental Biomaterials Market
The global dental bone grafting market is growing rapidly due to the increasing number of implant procedures and the aging population, and the results of this trial could change the criteria for product selection. In particular, if the injectable GTO, which maximizes procedural convenience, proves to be able to replace traditional granular products, Tecnoss will further solidify its position in the premium market. It is expected that this will accelerate the trend of clinicians adopting more advanced biomaterials to achieve both reduced surgical time and improved patient outcomes.
The global dental bone grafting and biomaterials market is estimated at approximately $680 million to $870 million in 2025, and is maintaining a high annual growth rate of 6.8% to 10.6% due to the increasing number of implant procedures. This trial is a key study to directly compare Tecnoss's porcine-derived GTO and Gen-Os, which are already on the market, in order to confirm the superiority in terms of procedural convenience and regenerative efficiency when used in minimally invasive non-incision papilla preservation techniques. In the short term, this will serve as an opportunity to strengthen the position of porcine collagen grafts and diversify the product portfolio in response to Geistlich Pharma's Bio-Oss, which dominates the bone-derived graft market. In the medium to long term, if the superiority of the temperature-sensitive hydrogel mixed material is proven and the adoption rate of injectable biomaterials increases, it is expected to play a role as a catalyst for structural changes in the global dental supply chain, which is currently centered on granular materials.
Source: ClinicalTrials.gov (api_ct)